Tandem Diabetes Care (NASDAQ:TNDM) Stock Price Down 7.4% – What’s Next?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) traded down 7.4% during trading on Tuesday. The company traded as low as $17.08 and last traded at $17.1150. Approximately 1,206,966 shares changed hands during mid-day trading, a decline of 44% from the average session volume of 2,171,074 shares. The stock had previously closed at $18.48.

Wall Street Analyst Weigh In

Several research firms recently commented on TNDM. Royal Bank Of Canada reissued an “outperform” rating and set a $26.00 target price (down from $30.00) on shares of Tandem Diabetes Care in a research note on Friday, August 7th. William Blair initiated coverage on shares of Tandem Diabetes Care in a research report on Friday, August 21st. They issued an “outperform” rating on the stock. UBS Group assumed coverage on Tandem Diabetes Care in a report on Tuesday, July 28th. They issued a “neutral” rating and a $18.00 price target on the stock. Truist Financial cut their price objective on Tandem Diabetes Care from $31.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, September 24th. Finally, Canaccord Genuity Group set a $40.00 price objective on Tandem Diabetes Care in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Tandem Diabetes Care currently has a consensus rating of “Hold” and an average target price of $27.18.

Check Out Our Latest Stock Report on Tandem Diabetes Care

Tandem Diabetes Care Price Performance

The stock has a 50 day moving average of $17.37 and a two-hundred day moving average of $18.83. The stock has a market cap of $1.19 billion, a PE ratio of -23.69 and a beta of 1.59. The company has a debt-to-equity ratio of 4.47, a quick ratio of 2.65 and a current ratio of 3.20.

Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.15. Tandem Diabetes Care had a negative return on equity of 35.61% and a negative net margin of 4.58%. The firm had revenue of $283.69 million for the quarter, compared to the consensus estimate of $265.85 million. During the same quarter in the previous year, the company earned ($0.31) EPS. The business’s revenue for the quarter was up 13.8% compared to the same quarter last year. Equities analysts anticipate that Tandem Diabetes Care, Inc. will post -0.61 EPS for the current year.

Insider Buying and Selling at Tandem Diabetes Care

In other news, Director Christopher J. Twomey sold 1,700 shares of the business’s stock in a transaction that occurred on Tuesday, October 27th. The shares were sold at an average price of $19.15, for a total transaction of $32,555.00. Following the sale, the director owned 24,434 shares in the company, valued at $467,911.10. The trade was a 6.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC acquired a new position in Tandem Diabetes Care in the 2nd quarter worth approximately $33,000. Sterling Capital Management LLC raised its stake in Tandem Diabetes Care by 849.0% during the 3rd quarter. Sterling Capital Management LLC now owns 2,325 shares of the medical device company’s stock valued at $38,000 after purchasing an additional 2,080 shares during the period. Fulcrum Asset Management LLP raised its stake in Tandem Diabetes Care by 1,463.6% during the 3rd quarter. Fulcrum Asset Management LLP now owns 4,378 shares of the medical device company’s stock valued at $73,000 after purchasing an additional 4,098 shares during the period. Provenance Wealth Advisors LLC purchased a new stake in shares of Tandem Diabetes Care in the third quarter valued at $158,000. Finally, Prosperitas Financial LLC purchased a new stake in shares of Tandem Diabetes Care in the second quarter valued at $151,000.

About Tandem Diabetes Care

(Get Free Report)

Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.

Featured Articles

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.